Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Novo Nordisk

Status and phase: Completed; Phase 1

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: liraglutide; Drug: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01509742

NN2211-1224

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.

Enrollment: 19 patients

Sex: All

Ages: 30 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

age: minimum 30, maximum 75 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

19 participants in 2 patient groups, including a placebo group

NNC 90-1170

Experimental group

Treatment:

Drug: liraglutide

Placebo

Placebo Comparator group

Treatment:

Drug: placebo